Melanotan 2 (MT-2)

What Is Melanotan 2?

Melanotan 2 is a synthetic, cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), developed around the same time as Melanotan 1 but with a different structure: a smaller, ring-shaped peptide rather than a linear chain. That structural difference changes which receptors it activates in the body.

Where Melanotan 1 was engineered to bind fairly selectively to the pigmentation receptor, Melanotan 2 activates a broader set of melanocortin receptors, including ones involved in appetite and sexual function. This broader activity is part of why an early human trial documented both pigmentation and other effects, including spontaneous erections, from the same compound.

What Melanotan 2 Is Being Researched For

• Skin Pigmentation

  Like Melanotan 1, MT-2's earliest research documented its ability to darken skin, established in a pilot Phase I human trial in the 1990s.^[1]

• Sexual Function

  Because MT-2 activates receptors beyond the pigmentation pathway, a distinct area of research examined its effect on erectile function, finding it could initiate erections in men with certain forms of erectile dysfunction.^[2]

• Safety and Risk Research

  Because MT-2 is sold outside regulated pharmaceutical channels, a body of research has specifically reviewed the safety risks associated with its unregulated use, including case reports of serious adverse effects.^[3]

How Melanotan 2 Works

• Activating Multiple Melanocortin Receptors

  Research points to MT-2 binding to several melanocortin receptors at once, including MC1R, involved in skin pigmentation, and MC3R and MC4R, involved in appetite regulation and sexual function. This broader receptor activity distinguishes it from more selective analogs in its class.^[1]

• A Central Nervous System Component

  Research points to MT-2's effect on sexual function working through both brain and spinal mechanisms, rather than acting locally, which is consistent with its activation of MC4R, a receptor found in the central nervous system.^[2]

• Documented Side Effects Tied to Its Broader Activity

  Research points to MT-2's non-selective receptor activity as the likely explanation for effects seen in early trials beyond pigmentation, including nausea, flushing, and spontaneous erections, effects not typically seen with the more MC1R-selective Melanotan 1.^[1]

Reconstitution and Handling

MT-2 is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Melanotan 2's defining feature is its broader, less selective activity across multiple melanocortin receptors, which is what produced both its pigmentation and sexual function effects in early research, and also what's tied to its distinct side effect profile. Unlike Melanotan 1, it has not progressed toward FDA approval, and a meaningful part of the published literature on MT-2 specifically addresses the risks of its unregulated use. That safety research is worth weighing directly alongside its mechanistic findings.

Frequently Asked Questions

Sources and Research

1. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784.
2. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646.
3. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980.